Clinical trial
Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of…
NCT00159640 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00159640 |
|---|---|
| Title | Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia |
| Official title | A Multi-Center, Randomized, Double Blind, Dose-Response, Placebo And Gabapentin Controlled Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pain |
| Intervention type | Drug |
| Interventions | PD-217, 014 |
| Enrollment | 315 |
| Start date | Feb 1, 2004 |
| First posted | Sep 12, 2005 |
| Last update posted | Mar 28, 2007 |
| Countries | Australia, Canada, Czechia, Netherlands, Spain, United Kingdom |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: